NCT05836532

Brief Summary

Mitral regurgitation is a pathology affecting the left atrioventricular valve that causes a volumetric and pressure overload in the left chambers due to the loss of unidirectionality normally guaranteed by the cardiac valve system. The gold standard for severe mitral regurgitation is currently mitral valve plastic surgery. Edge to edge, on the other hand, allows shorter CEC and aortic clamping times and does not require significant surgical experience in the field of mitral valve repair, therefore edge to edge could be an excellent strategy in patients suffering from mitral regurgitation caused by P2 prolapse when quadrangular resection cannot be performed. The main objective of the present study is to examine the medium to long-term outcomes (in terms of survival and plastic outcomes) of patients undergoing central edge-to-edge to treat posterior flap pathology (P2).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 5, 2019

Completed
10 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 15, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 15, 2019

Completed
3.3 years until next milestone

First Submitted

Initial submission to the registry

January 26, 2023

Completed
3 months until next milestone

First Posted

Study publicly available on registry

May 1, 2023

Completed
Last Updated

May 1, 2023

Status Verified

April 1, 2023

Enrollment Period

10 days

First QC Date

January 26, 2023

Last Update Submit

April 28, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • MR 2+ or more recurrency

    through study completion, a minimum of 2 years

Secondary Outcomes (1)

  • Reintervention

    through study completion, a minimum of 2 years

Interventions

Suture of free margins of the mitral leaflets in central position to restore coaptation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with degenerative MR, due to P2 prolapse, who underwent surgery with central edge to edge

You may qualify if:

  • Mitral regurgitation with degenerative etiology
  • Mitral pathology exclusively dependent on P2
  • Surgical creation of a double mitral valve orifice with or without a ring as the only mitral valve repair technique.

You may not qualify if:

  • \- Other mitral regurgitation etiologies (eg. functional, radiation-induced, rheumatic...)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS Ospedale San Raffaele - Cardiac Surgery Department

Milan, 20132, Italy

Location

MeSH Terms

Conditions

Mitral Valve Insufficiency

Condition Hierarchy (Ancestors)

Heart Valve DiseasesHeart DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Chief od Cardiac Surgery of Advanced and Research Therapies

Study Record Dates

First Submitted

January 26, 2023

First Posted

May 1, 2023

Study Start

October 5, 2019

Primary Completion

October 15, 2019

Study Completion

October 15, 2019

Last Updated

May 1, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

Locations